The effect of omega-3 fatty acids on clinical and paraclinical features of intractable epileptic patients: a triple blind randomized clinical trial

Clinical and Translational Medicine

Table 2 Baseline measurements in the study groups

Parameters	Study groups	Mean ± SD	Median [IQR]	P value
Age	Supplement	34.08 ± 10.6	32 [27.5, 41.5]	0.676
Age	Placebo	32.88 ± 10.7	32 [24.5, 40.5]	0.676
Seizure frequency in recent 4 months	Supplement	6.8 ± 4.3	5 [4, 10]	0.83
Seizure frequency in recent 4 months	Placebo	8.36 ± 7.3	6 [3.5, 11]	0.83
TNF-α levels	Supplement	24.98 ± 38.36	13.02 [3.67, 26.4]	0.258
TNF-α levels	Placebo	43.27 ± 46.7	22.4 [8.64, 68.25]	0.258
IL-6 levels	Supplement	4.37 ± 3.02	4.03 [2, 6.09]	0.684
IL-6 levels	Placebo	6.76 ± 11.58	4.37 [1.56, 6.43]	0.684
Epilepsy duration in recent 4 months (min)	Supplement	13.88 ± 7.45	10 [10, 20]	0.226
Epilepsy duration in recent 4 months (min)	Placebo	17.04 ± 9.07	10 [10, 30]	0.226